Companies / United States
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Eli Lilly Outsources More R&D
August 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
As a strategy, outsourcing forms a key part of US-based Eli Lilly's drive to streamline its R&D processes. Over the past few years, the company, like many multinational drugmakers, has been looking to outsource research functions to Asia in order to lower overheads. Eli Lilly has forged partnerships with China's Shanghai ChemPartner and Hutchison MediPharma (Chi-Med) for early-stage drug development and with Indian firms Nicholas Piramal and Suven Pharmaceuticals for R&D